Add like
Add dislike
Add to saved papers

Information System for Integration of Genetic Information and Clinical Knowledge.

This paper deals with a developed information system called a Personal Genetic Card (PGC). The system aims to integrate the known clinical knowledge (interpretations and recommendations) linked to genetic information with the analysis results of a patient. Genetic information has an increasing influence on the clinical decision of physicians as well as other medical and health services. All these services need to connect the genetic profile with the phenotypes such as drug metabolization, drug toxicity, drug dosing, or intolerance of some substances. It still applies that the best way to represent data of medical records is a structured form of record. Many approaches can be used to define the structure (syntax) of the record and the content (semantics) of the record and to exchange data in forms of various standards and terminologies. Moreover, the genetic analysis field has its terminology databases for representing genetic information (e.g. HGNC, NCBI). The next step is to connect the genetic analysis results with c clinical knowledge (interpretation, recommendation). This step is crucial because the genetic analysis results have clinical benefits if we can assign them to some valid clinical knowledge. And the best final result is when we can make a better recommendation based on the genetic results and clinical knowledge. Genetic knowledge databases (e.g. PharmGKB, SNPedia, ClinVar) contain many interpretations and even recommendations for genetic analysis results based on different purposes. This situation is appropriate for developing the PGC system that takes inspiration from case-based reasoning in purpose to allow integration of the assumptions and knowledge about phenotypes and the real genetic analysis results in the structured form.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app